Evaluation of the pharmacokinetics and metabolism of a novel histone deacetylase inhibitor, KBH-A40, in rats

References

• Artursson P, Borchardt RT. (1997). Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond. Pharm Res 14:1655–1658.
   PubMed Web of Science ®Google Scholar
• Artursson P, Palm K, Luthman K. (2001). Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 46:27–43.
   PubMed Web of Science ®Google Scholar
• Batty N, Malouf GG, Issa JP. (2009). Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett 280:192–200.
   PubMed Web of Science ®Google Scholar
• Charman WN, Rogge MC, Boddy AW, Barr WH, Berger BM. (1993). Absorption of danazol after administration to different sites of the gastrointestinal tract and the relationship to single- and double-peak phenomena in the plasma profiles. J Clin Pharmacol 33:1207–1213.
   Google Scholar
• Delie F, Rubas W. (1997). A human colonic cell line sharing similarities with enterocytes as a model to examine oral absorption: advantages and limitations of the Caco-2 model. Crit Rev Ther Drug Carrier Syst 14:221–286.
   PubMed Web of Science ®Google Scholar
• Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR. (2007). Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109:31–39.
   PubMed Web of Science ®Google Scholar
• Duvic M, Vu J. (2007). Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 16:1111–1120.
   PubMed Web of Science ®Google Scholar
• FDA labeling information [online]. 2006. <http://www.FDA.gov/cder/foi/label/2006/021991lbl.pdf>
   Google Scholar
• Fogh J, Fogh JM, Orfeo T. (1977). One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 59:221–226.
   PubMed Web of Science ®Google Scholar
• Gan L-SL, Thakker DR. (1997). Applications of the Caco-2 model in the design and development of orally active drugs: elucidation of biochemical and physical barriers posed by the intestinal epithelium. Adv Drug Deliv Rev 23:77–98.
   Web of Science ®Google Scholar
• Granero GE, Amidon GL. (2008). Possibility of enterohepatic recycling of ketoprofen in dogs. Int J Pharm 349:166–171.
   PubMed Web of Science ®Google Scholar
• Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. (2004). Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59:177–189.
   PubMed Web of Science ®Google Scholar
• Kim HM, Lee K, Park BW, Ryu DK, Kim K, Lee CW, Park SK, Han JW, Lee HY, Lee HY, Han G. (2006). Synthesis, enzymatic inhibition, and cancer cell growth inhibition of novel delta-lactam-based histone deacetylase (HDAC) inhibitors. Bioorg Med Chem Lett 16:4068–4070.
   PubMedGoogle Scholar
• Kim HM, Oh SJ, Park SK, Han G, Kim K, Lee KS, Kang JS, Nam M, Lee K. (2008). In vitro metabolism of KBH-A40, a novel delta-lactam-based histone deacetylase (HDAC) inhibitor, in human liver microsomes and serum. Xenobiotica 38:281–293.
   PubMed Web of Science ®Google Scholar
• Kim HM, Ryu DK, Choi Y, Park BW, Lee K, Han SB, Lee CW, Kang MR, Kang JS, Boovanahalli SK, Park SK, Han JW, Chun TG, Lee HY, Nam KY, Choi EH, Han G. (2007). Structure-activity relationship studies of a series of novel delta-lactam-based histone deacetylase inhibitors. J Med Chem 50:2737–2741.
   PubMedGoogle Scholar
• Lau GS, Critchley JA. (1994). The estimation of paracetamol and its major metabolites in both plasma and urine by a single high-performance liquid chromatography assay. J Pharm Biomed Anal 12:1563–1572.
   PubMed Web of Science ®Google Scholar
• Lee K, Thakker DR. (1999). Saturable transport of H2-antagonists ranitidine and famotidine across Caco-2 cell monolayers. J Pharm Sci 88:680–687.
   PubMed Web of Science ®Google Scholar
• Lin JH, Chiba M, Balani SK, Chen IW, Kwei GY, Vastag KJ, Nishime JA. (1996). Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos 24:1111–1120.
   PubMed Web of Science ®Google Scholar
• Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr, Evans RM. (1998). Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391:811–814.
   PubMed Web of Science ®Google Scholar
• Lipka E, Lee ID, Langguth P, Spahn-Langguth H, Mutschler E, Amidon GL. (1995). Celiprolol double-peak occurrence and gastric motility: nonlinear mixed effects modeling of bioavailability data obtained in dogs. J Pharmacokinet Biopharm 23:267–286.
   PubMedGoogle Scholar
• Lu C, Li P, Gallegos R, Uttamsingh V, Xia CQ, Miwa GT, Balani SK, Gan LS. (2006). Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes. Drug Metab Dispos 34:1600–1605.
   PubMed Web of Science ®Google Scholar
• Mottet D, Castronovo V. (2008). Histone deacetylases: target enzymes for cancer therapy. Clin Exp Metastasis 25:183–189.
   PubMed Web of Science ®Google Scholar
• Mummaneni V, Amidon GL, Dressman JB. (1995). Gastric pH influences the appearance of double peaks in the plasma concentration-time profiles of cimetidine after oral administration in dogs. Pharm Res 12:780–786.
   PubMed Web of Science ®Google Scholar
• Ng SP, Wong KY, Zhang L, Zuo Z, Lin G. (2004). Evaluation of the first-pass glucuronidation of selected flavones in gut by Caco-2 monolayer model. J Pharm Pharm Sci 8:1–9.
   PubMed Web of Science ®Google Scholar
• Pang KS, Rowland M. (1977). Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625–653.
   PubMedGoogle Scholar
• Plusquellec Y, Campistron G, Staveris S, Barre J, Jung L, Tillement JP, Houin G. (1987). A double-peak phenomenon in the pharmacokinetics of veralipride after oral administration: a double-site model for drug absorption. J Pharmacokinet Biopharm 15:225–239.
   PubMedGoogle Scholar
• Press B, Di Grandi D. (2008). Permeability for intestinal absorption: Caco-2 assay and related issues. Curr Drug Metab 9:893–900.
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Subramanian R, Fang X, Ma B, Qiu Y, Lin JH, Pearson PG, Baillie TA. (2002). Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 30:505–512.
   PubMed Web of Science ®Google Scholar
• Roberts MS, Magnusson BM, Burczynski FJ, Weiss M. (2002). Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet 41:751–790.
   PubMed Web of Science ®Google Scholar
• Shelnutt SR, Cimino CO, Wiggins PA, Ronis MJ, Badger TM. (2002). Pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein in men and women after consumption of a soy beverage. Am J Clin Nutr 76:588–594.
   PubMed Web of Science ®Google Scholar
• Sun H, Chow EC, Liu S, Du Y, Pang KS. (2008). The Caco-2 cell monolayer: usefulness and limitations. Expert Opin Drug Metab Toxicol 4:395–411.
   PubMed Web of Science ®Google Scholar
• van Breemen RB, Li Y. (2005). Caco-2 cell permeability assays to measure drug absorption. Expert Opin Drug Metab Toxicol 1:175–185.
   PubMedGoogle Scholar
• Wang Y, Roy A, Sun L, Lau CE. (1999). A double-peak phenomenon in the pharmacokinetics of alprazolam after oral administration. Drug Metab Dispos 27:855–859.
   PubMed Web of Science ®Google Scholar
• Weitschies W, Bernsdorf A, Giessmann T, Zschiesche M, Modess C, Hartmann V, Mrazek C, Wegner D, Nagel S, Siegmund W. (2005). The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen. Pharm Res 22:728–735.
   PubMed Web of Science ®Google Scholar
• Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Göttlicher M. (2004). Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5:455–463.
   PubMed Web of Science ®Google Scholar